Glucagon-like peptide-1-receptor agonists (GLP-1RA) are medications that are increasingly prescribed for patients with type 2 ...

For patients with opioid use disorder (OUD) and alcohol use disorder (AUD), prescriptions of glucose-dependent insulinotropic ...

The demand for bariatric operations dropped sharply last year as use of anti-obesity drugs such as Wegovy surged, study finds ...

Reviewed by Dietitian Emily Lachtrupp, M.S., RD Ever since berberine made headlines last year for being touted as “nature’s ...

News and talk of GLP-1 drugs are everywhere these days—from their smash success in treating Type 2 diabetes and obesity to ...

A new study by researchers at Brigham and Women's Hospital in collaboration with researchers at Harvard T.H. Chan School of ...

Centene's Medicaid revenue fell slightly in the third quarter as costs outpaced the payment increases states implemented.

A new study reveals that the active ingredient in drugs like Ozempic and Wegovy could lower the risk of developing ...

Amgen Inc.'s Q3 earnings may not be a major upside, but new pipeline drugs and potential breakthroughs could drive growth.

Taking a GLP-1 receptor agonist was associated with a lower risk for cirrhosis and related complications in patients with ...

Multiple sessions and virtual care companies touted the potential of glucagon-like peptide-1 agonist drugs to help patients ...

A new study has examined a large sample of privately insured patients with obesity and found that use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as anti-obesity medications more than ...